Home > Dermatology > SPIN 2022 > Best of the Posters > Dose tapering in psoriasis is associated with a low relapse rate

Dose tapering in psoriasis is associated with a low relapse rate

Presented By
Dr Juan Raul Castro Ayarza , Medicarte, Colombia
SPIN 2022
Among investigated psoriasis patients receiving biologics, 88% remained in sustained clinical response after 8 months of dose tapering. The low relapse rate, together with remarkable cost savings, supports this approach as an effective strategy for treating psoriasis. Biologic therapy results in long-term low disease activity or even clinical remission in patients with moderate-to-severe psoriasis; the downside is the high costs. Dr Juan Raul Castro Ayarza (Medicarte, Colombia) and his team performed a cohort study to investigate whether optimisation of treatment by a progressive dose reduction or increase of the administration interval can still prevent relapses in these patients [1]. Patients presenting with psoriasis to a specialised, multicentre health institution in Colombia who were above 18 years of age and treated with biologic therapy with a sustained response for at least 12 months were included. They were treated with different biologica...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on